Germany · Delayed Price · Currency is EUR SCHOTT Pharma AG & Co. KGaA Earnings Call Transcripts
Fiscal Year 2026
-
H1 2026 saw resilient revenue and EBITDA growth, led by DCS and high-value solutions, while DDS faced temporary headwinds due to a one-off impairment. Guidance for FY 2026 is reaffirmed, with strong order book visibility and strategic investments supporting future growth.
-
Q1 2026 saw revenue up 4.8% at constant currencies and EBITDA margin rise to 27.1%, driven by strong demand for high-value solutions. Guidance for FY 2026 is maintained, with expected revenue growth of 2%-5% and continued investment in capacity expansion.
Fiscal Year 2025
-
Revenue grew 3% to EUR 986 million in 2025, with high-value solutions at 57% of sales and EBITDA margin up to 28.4%. 2026 guidance anticipates 2%-5% revenue growth and a 27% EBITDA margin, with GLP-1 and specialty vials as key drivers amid lower mRNA and vaccine demand.
-
Q3 revenue grew 3% year-over-year to €256 million, with EBITDA up 11% to €83 million and a record 31.7% margin, driven by high-value solutions. FY2025 guidance is for 6% organic revenue growth and a 28% EBITDA margin, with continued investment in capacity and innovation.
-
Q2 2025 saw revenues and EBITDA exceed expectations, driven by strong HVS demand and efficiency gains. Both DCS and DDS segments contributed to growth, with innovation and expansion supporting future performance. Full-year guidance is maintained amid market volatility.
-
Q1 2025 saw stable revenues of EUR 230 million, with strong HVS demand and robust order intake in vials, especially in EMEA and North America. EBITDA margin was 26.3% at constant currencies, and full-year guidance for high single-digit revenue growth and stable margins is confirmed.
Fiscal Year 2024
-
Revenue and profitability exceeded targets in 2024, driven by high-value solutions and strong DDS growth. 2025 guidance anticipates high single-digit revenue growth, stable EBITDA margin, and back-end loaded performance amid market volatility.
-
Q3 saw record revenue and EBITDA growth, driven by strong DDS demand and capacity expansion, with HVS share reaching 53%. Full-year revenue guidance was raised to 11%-13%, and robust market trends in GLP-1, mRNA, and ADCs support a positive outlook.